Fragile X Syndrome: Symptoms, Diagnosis, Treatments and Complications: By Shreoshree Chakrabarty Fragile X Syndrome (FXS), also known as FX syndrome or fragile syndrome, is the most common inherited ...

Research on fragile X syndrome, the most common inherited cause of mental retardation, has focused mostly on how the genetic defect alters the functioning of neurons in the brain. A new study focusing ...

A new study suggests a potential molecular strategy for treating fragile X syndrome, an inherited neurodevelopmental disorder that causes autism spectrum disorder and intellectual disability. This ...

Mutations in FMR1, the gene encoding fragile X messenger ribonucleoprotein 1 (FMRP), located at Xq27.3 and discovered in 1991, are the leading single-gene causes of autism and intellectual disability.

Scientists have created a new therapeutic approach for testing fragile X syndrome, which is the most common genetic cause of autism spectrum disorder (ASD). This method aims to alter a type of neural ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will ...

Les Laboratoires Servier said that it agreed to acquire a potential treatment for Fragile X syndrome (FXS), the most common genetic cause of autism spectrum disorder (ASD), from its original developer ...

Observations of the small protrusions that line the dendrites of neurons, called spines, were critical in understanding the function of NMDA receptors in the new study, as well as a precursor to the ...

UC Davis MIND Institute researchers Randi and Paul Hagerman are calling for increased awareness and screening for fragile X-associated conditions. In a new paper published in the New England Journal ...

Proof-of-concept study underway for investigational oral therapy in Fragile X syndrome; top-line data from Phase 2 expected in 2027 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease ...

Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals Enthorin Therapeutics, LLC, a ...